Market Place
Sourcing Support
Neurocrine Highlights INGREZZA Efficacy in Tardive Dyskinesia
08 Jun 2026 //
PR NEWSWIRE
Neurocrine to Present Two-Year Crenessity Data at ENDO 2026
03 Jun 2026 //
PR NEWSWIRE
Neurocrine Biosciences to Present at June Investor Conferences
27 May 2026 //
PR NEWSWIRE
Neurocrine`s Ingrezza Effective in Mild Tardive Dyskinesia
19 May 2026 //
PR NEWSWIRE
Neurocrine Biosciences Completes Soleno Therapeutics Acquisition
18 May 2026 //
PR NEWSWIRE
Neurocrine Publishes Glucocorticoid Dose Reduction Guidelines
06 May 2026 //
PR NEWSWIRE
Neurocrine Biosciences Unveils Q1 2026 Financial Results
06 May 2026 //
PR NEWSWIRE
Neurocrine to Present at BofA Health Care Conference 2026
05 May 2026 //
PR NEWSWIRE
Neurocrine Survey Reveals Tardive Dyskinesia`s Toll on Jobs
04 May 2026 //
PR NEWSWIRE
Neurocrine Starts Phase 1 Study of CRF2 Agonist NBIP-2118
04 May 2026 //
PR NEWSWIRE
Neurocrine Biosciences Shows Durable Hormone Control
01 May 2026 //
PR NEWSWIRE
Neurocrine Establishes Threshold for TD Impact Scale
29 Apr 2026 //
FIRSTWORD PHARMA
Neurocrine Presents Two-Year CRENESSITY Data in CAH Adults
23 Apr 2026 //
PR NEWSWIRE
Neurocrine Buys Soleno at Discount as Europe Prospects Fade
21 Apr 2026 //
ENDPOINTS NEWS
Neurocrine Biosciences Announces Q1 2026 Earnings Call, Webcast
15 Apr 2026 //
PR NEWSWIRE
Neurocrine Biosciences Shows INGREZZA Outperforms AUSTEDO XR
14 Apr 2026 //
PR NEWSWIRE
Nxera Pharma Initiates Phase 2 Trial Of NBI-1117570
12 Apr 2026 //
GLOBENEWSWIRE
Neurocrine expands into metabolic diseases with $2.9 billion Sole
06 Apr 2026 //
REUTERS
Neurocrine Biosciences Presents on Tardive Dyskinesia
26 Mar 2026 //
PR NEWSWIRE
Neurocrine Biosciences Names Ratz Chief Technical Ops Officer
18 Mar 2026 //
PR NEWSWIRE
Neurocrine Biosciences To Present At Stifel 2026 CNS Forum
10 Mar 2026 //
PR NEWSWIRE BIO
Neurocrine Biosciences To Present At March Investor Conferences
24 Feb 2026 //
PR NEWSWIRE
Neurocrine Biosciences Reports 2025 Results and 2026 Outlook
11 Feb 2026 //
PR NEWSWIRE
Neurocrine Biosciences Starts Phase 2 Trial For NBI-1065890
26 Jan 2026 //
PR NEWSWIRE BIO
Neurocrine Biosciences Announces Q4 2025 Earnings
21 Jan 2026 //
PR NEWSWIRE
Neurocrine Biosciences Shows INGREZZA Outperforms AUSTEDO XR
15 Jan 2026 //
PR NEWSWIRE
Neurocrine Biosciences at 44th J.P. Morgan Healthcare Conference
05 Jan 2026 //
PR NEWSWIRE
Neurocrine`s Movement Disorder Treatment Fails Late-Stage Trial
23 Dec 2025 //
BIOSPACE
Neurocrine Biosciences Highlights R&D Transformation
16 Dec 2025 //
PR NEWSWIRE
Neurocrine Biosciences To Host R&D Day On December 16
10 Dec 2025 //
PR NEWSWIRE
Neurocrine`s Review Contrasts Tardive Dyskinesia Drugs
23 Nov 2025 //
INDPHARMAPOST
Neurocrine Publishes Review Highlighting Unique INGREZZA Profile
20 Nov 2025 //
PR NEWSWIRE
Neurocrine Biosciences To Present At Investor Conferences
12 Nov 2025 //
PR NEWSWIRE
Neurocrine-Takeda Psychiatry Pact Suffers Another Phase 2 Fail
11 Nov 2025 //
FIERCE BIOTECH
Neurocrine Biosciences Updates Phase 2 Study Of NBI-1070770
11 Nov 2025 //
PR NEWSWIRE
Neurocrine Pens $880M Pact With Transthera For Immunology Target
04 Nov 2025 //
FIERCE BIOTECH
Neurocrine Biosciences Releases Q3 2025 Financial Results
29 Oct 2025 //
PR NEWSWIRE
Neurocrine Shows INGREZZA Efficacy in KINECT 4 Analysis
17 Oct 2025 //
PR NEWSWIRE
Neurocrine Biosciences To Host Conference Call For Q3 2025
07 Oct 2025 //
PR NEWSWIRE
Neurocrine Bio Appoints Mike Sibley as Senior Vice President
06 Oct 2025 //
PR NEWSWIRE
Neurocrine Biosciences Shows Ingrezza Sustained Benefits
06 Oct 2025 //
PR NEWSWIRE
Neurocrine Biosciences Shows Ingrezza® Capsules Prompt Early
23 Sep 2025 //
PR NEWSWIRE
Neurocrine Reports Positive Ph 2 Osavampator Data In MDD
22 Sep 2025 //
PR NEWSWIRE
Neurocrine Biosciences to Unveil Osavampator Phase 2 Data
17 Sep 2025 //
PR NEWSWIRE
Neurocrine Biosciences to Present at Investor Conferences
26 Aug 2025 //
PR NEWSWIRE
Neurocrine Biosciences to Present at Canaccord Genuity Conference
07 Aug 2025 //
PR NEWSWIRE
Neurocrine Biosciences` Q2 2025 Financial Results Released
30 Jul 2025 //
PR NEWSWIRE
Neurocrine Uses PicnicHealth to Identify Gaps in Rare Conditions
15 Jul 2025 //
PR NEWSWIRE
Neurocrine Reveals CAHtalog® Data at ENDO 2025
15 Jul 2025 //
PR NEWSWIRE
Neurocrine Shows 1-Year CRENESSITY® Results at ENDO 2025
14 Jul 2025 //
PR NEWSWIRE
Neurocrine Shares CAHtalyst™ 1-Year Data at ENDO 2025
14 Jul 2025 //
PR NEWSWIRE
Neurocrine Biosciences Schedules Q2 2025 Financial Results Call
09 Jul 2025 //
PR NEWSWIRE
Neurocrine Biosciences Starts Phase 1 Study for NBIP-01435
30 Jun 2025 //
PR NEWSWIRE
Neurocrine: Ingezza Cuts HD Chorea Burden in KINECT-HD Study
27 Jun 2025 //
PR NEWSWIRE
Neurocrine Reports Ingrezza HRQoL Gains in TD Patients
20 Jun 2025 //
PR NEWSWIRE
Nxera Pharma gets US$15M from Neurocrine Biosciences for Phase 3
02 Jun 2025 //
GLOBENEWSWIRE
Neurocrine Shows INGREZZA Improved QoL In Tardive Dyskinesia
02 Jun 2025 //
PR NEWSWIRE
Neurocrine Shares Ph 2 of NBI-1117568 Data On Schizophrenia Drug
28 May 2025 //
PR NEWSWIRE
Neurocrine Biosciences Presents Positive Data on NBI-1117568
28 May 2025 //
GLOBENEWSWIRE
Neurocrine Biosciences Presents Data on Tardive Dyskinesia
16 May 2025 //
PR NEWSWIRE
